Eosinophils and interleukin-5: the debate continues.
Kay
A Barry
AB
Menzies-Gow
Andrew
A
D018927:Anti-Asthmatic Agents / Q000276:immunology / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D001249:Asthma / Q000150:complications / Q000188:drug therapy* / Q000276:immunology; D017322:Clinical Trials, Phase II as Topic; D004802:Eosinophilia / Q000097:blood / Q000209:etiology; D004804:Eosinophils / Q000187:drug effects* / Q000276:immunology; D005541:Forced Expiratory Volume / Q000187:drug effects; D006801:Humans; D015848:Interleukin-5 / Q000037:antagonists & inhibitors* / Q000276:immunology
D018927:Anti-Asthmatic Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D015848:Interleukin-5; C434107:mepolizumab